Leronlimab has also been studied in COVID-19 clinical trials, but the largely unfavorable efficacy outcomes in studies may be a consequence of leronlimab being a potent CCR5 ligand and HIV entry inhibitor, but with limited functional antagonistic properties against cognate ligand signaling [71–73]. This evidence concerns the gene CCR5 and COVID-19.